(+)-JQ1

For research use only. Not for use in humans.

目录号:S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1是一种BET bromodomain抑制剂,作用于BRD4(1/2),无细胞试验中IC50为77 nM/33 nM,结合到BET家族的所有溴结构域,而不结合到BET家族以外的溴结构域。(+)-JQ1可通过诱导自噬来抑制细胞增殖。

规格 价格 库存 购买数量  
RMB 2227.39 现货
RMB 4667.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的(+)-JQ1发表文献217篇:

产品安全说明书

Target Protein Ligand抑制剂选择性比较

生物活性

产品描述 (+)-JQ1是一种BET bromodomain抑制剂,作用于BRD4(1/2),无细胞试验中IC50为77 nM/33 nM,结合到BET家族的所有溴结构域,而不结合到BET家族以外的溴结构域。(+)-JQ1可通过诱导自噬来抑制细胞增殖。
特性 (+)-JQ1比(-)-JQ1更有效。
靶点
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
体外研究

(+)-JQ1对映体直接结合到BET bromodomain结构域的Kac结合位点。(+)-JQ1(500 nM)与染色质竞争性结合到BRD4,导致NMC细胞分化和生长停滞。通过Ki67染色减少,证明了(+)-JQ1(500 nM)减弱NMC 797和Per403细胞系的快速增殖。(+)-JQ1(500 nM)作用于NMC 797细胞,有效降低BRD4靶基因的表达。(+)-JQ1作用于NMC 11060细胞,抑制细胞活力, IC50为4 nM。[1](+)-JQ1作用于MM细胞系,强抑制MYC表达。(+)-JQ1抑制KMS-34和LR5增殖,IC50分别为 68 nM和98 nM。(+)-JQ1(500 nM)处理MM.1S细胞,导致S期细胞比例明显下降,随之细胞停滞在G0/G1期增多。(+)-JQ1(500 nM)通过β-半乳糖苷酶染色,导致明显的细胞衰老。(+)-JQ1(800 nM)处理CD138+病患衍生的MM样本,显著降低细胞活力。[2] (+)-JQ1抑制LP-1细胞生长,GI50 为98 nM。(+)-JQ1(625 nM)导致LP-1细胞在G0/G1期的百分数增高。(+)-JQ1(500 nM)作用于LP-1细胞,抑制MYC, BRD4 和CDK9表达。[3](+)-JQ1(1 μM)处理潜伏感染的Jurkat T细胞,激活HIV转录。(+)-JQ1(50 μM)作用于Jurkat和HeLa细胞,主要刺激Tat依赖性的HIV转录。(+)-JQ1(5 μM)作用于J-Lat A2细胞,诱导Brd4解离,从而使Tat招募SEC到HIV启动子上,诱导Pol II CTD磷酸化和病毒转录。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NXy4OZlIS2WubDDWbYFjcWyrdImgRZN{[Xl? MWGyOVAwPTByL{GwNFAhdk1? NIDuboszPC92OD:3NkBp MnPVSG1UVw>? NIq2cIlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NXHINJM2OjZ5MEe4PFE>
BCPAP MlrSR4VtdCCYaXHibYxqfHliQYPzZZk> M4TINlI2OC93MECvNVAxOCCwTR?= NH\KUo4zPC92OD:3NkBp NVjqZ3ZUTE2VTx?= NFXHZVZqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MXeyOlcxPzh6MR?=
K1  MlXFR4VtdCCFeXPs[UBCe3OjeR?= Mn\tNlUxNzVyMD:xNFAxKG6P M2\j[|czKGh? NWPxXGZYTE2VTx?= MWThdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? NVLZNHhMOjZ5MEe4PFE>
BCPAP MmnQR4VtdCCFeXPs[UBCe3OjeR?= NXHaV3NpOjVyL{WwNE8yODByIH7N MWe3NkBp NXPmTFFxTE2VTx?= NUHXSVdC[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl NEPkZYwzPjdyN{i4NS=>
Hep3B MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jJblAuOTBizszN MUO1JIQ> NH;wUGVFVVOR M3fpTGlEPTB;MD6wPEDPxE1? NFmz[XUzPjV5NUG2Oy=>
HCCLM3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXkNGUxNTFyIN88US=> NF3xV3k2KGR? NIfac2lFVVOR MnHJTWM2OD1yLkG0JO69VQ>? MoDSNlY2PzVzNke=
HuH7 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[wNE0yOCEQvF2= M2PCZVUh\A>? MXnEUXNQ Mn2zTWM2OD1yLkKxJO69VQ>? NV\STVFsOjZ3N{WxOlc>
HepG2 NEXHV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTLNE0yOCEQvF2= MV61JIQ> NFzIO4dFVVOR NV\Be4d3UUN3ME2wMlM1KM7:TR?= MkTUNlY2PzVzNke=
SMMC7721 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[wMVExKM7:TR?= MoTiOUBl MoP3SG1UVw>? M2PG[WlEPTB;MD60NUDPxE1? NX65OlFuOjZ3N{WxOlc>
BEL7402 M1XOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnpXZoxNTFyIN88US=> MWe1JIQ> M{nHNWROW09? NV7uVYZ2UUN3ME2wMlQ4KM7:TR?= NVr5do9IOjZ3N{WxOlc>
MHCC97H MnOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;aNE0yOCEQvF2= NUH2VpVMPSCm MYDEUXNQ MmPHTWM2OD1yLkSxJO69VQ>? NEn4XGwzPjV5NUG2Oy=>
Hep3B NES4VG5E\WyuIFP5Z4xmKEG|c3H5 NVHoeVlzOC5zL{CuOU8zNjVizszN M1S4O|Q5KGh? MV7EUXNQ NVjUdXBidGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NUTTWnYxOjZ3N{WxOlc>
HCCLM3 M4Kwd2NmdGxiQ4njcIUhSXO|YYm= MXGwMlEwOC53L{KuOUDPxE1? MVq0PEBp MYjEUXNQ MkS5cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh NVr1bphIOjZ3N{WxOlc>
Hep3B MXfBdI9xfG:|aYOgRZN{[Xl? MmDONE4yNzBwNT:yMlUh|ryP NHHNXmE1QCCq NFPldotFVVOR M{S5doFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NI\PTmMzPjV5NUG2Oy=>
HCCLM3 M{LnUGFxd3C2b4Ppd{BCe3OjeR?= MkTuNE4yNzBwNT:yMlUh|ryP MknZOFghcA>? NInrRVdFVVOR NULSWo92[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NEDaZWYzPjV5NUG2Oy=>
A549 NFfZUXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWwMlEuOTBizszN NWjibmloPzJiaB?= NFL2bYhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2nZO|I3PDF3MkK1
H157 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVywMlEuOTBizszN NET0dHQ4OiCq NHfORWRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3;jVVI3PDF3MkK1
H1299 NFG5e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[wMlEuOTBizszN NYXtfWxOPzJiaB?= MnXrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWGyOlQyPTJ{NR?=
A549 NF;YdlNHfW6ldHnvckBCe3OjeR?= NHX1XHQyNzJwNT:1JO69VQ>? Mny0NVIhcA>? MkTSxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? NW[1R2NYOjZ2MUWyNlU>
H1299 NX33b|dVTnWwY4Tpc44hSXO|YYm= MlHrNU8zNjVxNTFOwG0> MYCxNkBp MWhCpJdm[WuueTDk[YNz\WG|ZXSgRoNtNTJibHX2[Yx{ NYTEO5Z1OjZ2MUWyNlU>
H157 MV\GeY5kfGmxbjDBd5NigQ>? M3\Z[|EwOi53L{Wg{txO NVXRb2xSOTJiaB?= NGHmXZpl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M4\NeFI3PDF3MkK1
H1299 MnnHSpVv[3Srb36gRZN{[Xl? NVzicGhvOS9{LkWvOUDPxE1? M2jjU|EzKGh? MoKz[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w NILvcZIzPjRzNUKyOS=>
C8161 MknCR4VtdCCYaXHibYxqfHliQYPzZZk> NF;vc3QxNTJizszN NV64WXhtPCCm MoPZSG1UVw>? NEe0Rlll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGrWR28zPjN7N{KyNy=>
Mel285 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4jGfVAuOiEQvF2= NWTY[21KPCCm NYnsWFNITE2VTx?= MlTi[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3vI[VI3Ozl5MkKz
Mel290 MoTHR4VtdCCYaXHibYxqfHliQYPzZZk> MUWwMVIh|ryP NV72PZNbPCCm MkK4SG1UVw>? NEPmT4Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3Lkc|I3Ozl5MkKz
92.1 NWn4SJoxS2WubDDWbYFjcWyrdImgRZN{[Xl? MWewMVIh|ryP NIrj[Fc1KGR? NUPZcIR4TE2VTx?= NWe1[|Rj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NX;JU2llOjZ|OUeyNlM>
Omm1.3 M4TOdGNmdGxiVnnhZoltcXS7IFHzd4F6 NF\JPZkxNTJizszN NWK3N3hvPCCm M2XzXGROW09? MnT6[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{TNRlI3Ozl5MkKz
Mel202 MmfTR4VtdCCYaXHibYxqfHliQYPzZZk> MVuwMVIh|ryP MkHnOEBl NHrwPYxFVVOR M3PFeYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn3qNlY{QTd{MkO=
Mel270 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> Mmi5NE0zKM7:TR?= M4PyV|Qh\A>? M{DRbWROW09? Mmjk[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIjFOYUzPjN7N{KyNy=>
Omm1 NHnZN3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mnr1NE0zKM7:TR?= M4nBdVQh\A>? MknCSG1UVw>? MoL0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Ml\iNlY{QTd{MkO=
92.1 MXjBdI9xfG:|aYOgRZN{[Xl? MYm1NFAhdk1? NHW5VnM1QCCq M{\xeGROW09? M4LWNolv\HWlZYOgZZBweHSxc3nz MVWyOlM6PzJ{Mx?=
Omm1.3 MYjBdI9xfG:|aYOgRZN{[Xl? NYG0NoR7PTByIH7N NYjOSGcyPDhiaB?= M1zYTWROW09? MmPxbY5lfWOnczDhdI9xfG:|aYO= MXuyOlM6PzJ{Mx?=
92.1 MlzTR4VtdCCFeXPs[UBCe3OjeR?= MXG1NFAhdk1? M1nJSlI1NzR6L{eyJIg> M3\XeWROW09? NVrMc2h{cW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= MknGNlY{QTd{MkO=
Omm1.3 MXvD[YxtKEO7Y3zlJGF{e2G7 MWq1NFAhdk1? NH7pU4gzPC92OD:3NkBp MUnEUXNQ MU\pcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NWnuSYR4OjZ|OUeyNlM>
A549 MmfFSpVv[3Srb36gRZN{[Xl? NEnvRYcyODBxNECwM|ExODBibl2= M2mxWVI1KGh? Mmq2eZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? M{X4fFI3OjF{MUm5
MCF-7 M3jPUWZ2dmO2aX;uJGF{e2G7 MXOxNFAwPDByL{GwNFAhdk1? MofmNlQhcA>? M3\T[ZVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NHG4VoIzPjJzMkG5PS=>
HEK293 MUXGeY5kfGmxbjDBd5NigQ>? MWSxNFAwPDByL{GwNFAhdk1? MmHRNlQhcA>? NWDER4FufXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NI\Fd5UzPjJzMkG5PS=>
858 NHH1WmdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEXwbnoxNTFizszN NV\oRnlKPSCm NXy3O4UzTE2VTx?= NYTLUldu\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWSyOlIxPjN|Mx?=
DDR2L63V NGHtfIVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVTjSXRjOC1zIN88US=> M3nZUlUh\A>? NHfrfYZFVVOR NYD2W49[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUnBSIp3OjZ{ME[zN|M>
BE(2)-C NHexfFRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:xJO69VQ>? MWqxMVQh\A>? MYDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MmH5NlYxPjd2NkS=
IMR-32 NWSxXoJ1S2WubDDWbYFjcWyrdImgRZN{[Xl? NFr2b3cyKM7:TR?= NHj3O2EyNTRiZB?= NEHKfGFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NVTYWppUOjZyNke0OlQ>
JF NV21Sld2S2WubDDWbYFjcWyrdImgRZN{[Xl? M4frVFEh|ryP MVGxMVQh\A>? NX3rbphD\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M2jNc|I3ODZ5NE[0
BE(2)-M17 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MXqxJO69VQ>? NVTTRmx2OS12IHS= NGLCRnRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? Mn6zNlYxPjd2NkS=
SK-N-SH MlXFR4VtdCCYaXHibYxqfHliQYPzZZk> MUSxJO69VQ>? NW\ZW5REOS12IHS= M1;RWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NHzqXVAzPjB4N{S2OC=>
SK-N-DZ  NVzXW5g5S2WubDDWbYFjcWyrdImgRZN{[Xl? NXXtTGFqOSEQvF2= NXHrSZkzOS12IHS= NUH1RZR5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MX6yOlA3PzR4NB?=
HMC-1.1  NHXLbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[1MVUxODBibl2= MWe0PEBp M2XuVmROW09? NGrkVHNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mln6NlYxPTV|MEO=
HMC-1.2 NVXZdJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13V[FUuPTByMDDuUS=> NXrjXXpzPDhiaB?= NVTvfZh1TE2VTx?= MWHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVeyOlA2PTNyMx?=
ROSA KIT WT  Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\TfopwPS13MECwJI5O Mlv6OFghcA>? MX3EUXNQ MlPnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXrvR2xnOjZyNUWzNFM>
ROSA KIT D816V NHzEepFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXyPFI2NTVyMECgcm0> M{nHU|Q5KGh? MVnEUXNQ M3TuXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHXM[pczPjB3NUOwNy=>
HMC-1.1  MnPLRZBweHSxc3nzJGF{e2G7 M3K3OVIxOC13MECwJI5O NETXR3g1QCCq MX7EUXNQ MVjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkDvNlYxPTV|MEO=
HMC-1.2 MoHhRZBweHSxc3nzJGF{e2G7 MVGyNFAuPTByMDDuUS=> M2nXUVQ5KGh? NGjrRpBFVVOR Mn;3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4P0Z|I3ODV3M{Cz
ROSA KIT WT  MnzURZBweHSxc3nzJGF{e2G7 M{C1b|IxOC13MECwJI5O MWW0PEBp NI\a[lJFVVOR NHfi[3hqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1Txc|I3ODV3M{Cz
ROSA KIT D816V MVLBdI9xfG:|aYOgRZN{[Xl? MYSyNFAuPTByMDDuUS=> NEHGOYw1QCCq MVnEUXNQ Mn;jbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M3K2eVI3ODV3M{Cz
494H NWXZcYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fFWlczKGh? MXLEUXNQ MnzLTWM2OD1yLkGyNuKyOC5yMESg{txO NYL1[mRSOjV7NES1OlY>
493H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M172RlczKGh? NEH0TJdFVVOR Ml\wTWM2OD1yLkC0O:KyOC5yMEmg{txO MYiyOVk1PDV4Nh?=
716H NYG2Nmk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYe3NkBp NFfjV4ZFVVOR MUPJR|UxRTBwMkGyxtExNjB|NDFOwG0> Mm\1NlU6PDR3Nk[=
148I M3roOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PjN|czKGh? MoT3SG1UVw>? NGPpRYVKSzVyPUCuNlg1yrFyLkCzOUDPxE1? NXmxcVRCOjV7NES1OlY>
98Sc NEjlS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NkBp MVrEUXNQ NEHBXWRKSzVyPUCuNVE2yrFyLkCwOEDPxE1? NIDnZWUzPTl2NEW2Oi=>
89R M{P4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp NEHkfJRFVVOR MYjJR|UxRTBwMUK2xtExNjByMzFOwG0> MnrKNlU6PDR3Nk[=
494L NIrQRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz2OZI4OiCq NF3wOWZFVVOR M{O0XWlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? MnHvNlU6PDR3Nk[=
493L NGP6SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[3NkBp MUTEUXNQ NIG1dVVKSzVyPUCuNFUxyrFyLkCxNUDPxE1? NG\NeGIzPTl2NEW2Oi=>
148L Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDMVnBkPzJiaB?= NXXFSG9KTE2VTx?= MYHJR|UxRTBwMUS2xtExNjBzNzFOwG0> MUCyOVk1PDV4Nh?=
98L M3LSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYq3NkBp M33ZXWROW09? M3zzNGlEPTB;MD6zNFnDuTBwMEK5JO69VQ>? NFLRbIozPTl2NEW2Oi=>
OS17 NIXa[lFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn23O|IhcA>? NWPT[WJTTE2VTx?= NG\KXIRKSzVyPUCuNFc6yrFyLkCwN{DPxE1? M4HRO|I2QTR2NU[2
OS9 NHG2SYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu3NkBp M3y0d2ROW09? NYPJT21EUUN3ME2wMlQxPsLzMD6wNlgh|ryP NWSy[Gh[OjV7NES1OlY>
MG63 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUS3NkBp MlfySG1UVw>? M1z6VWlEPTB;MD6xNVTDuTBwMEK1JO69VQ>? NID6UVAzPTl2NEW2Oi=>
SAOS2 M2THfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVj1W2k3PzJiaB?= M3z2NWROW09? M4XvSmlEPTB;MD6yNVfDuTBwMECzJO69VQ>? MX:yOVk1PDV4Nh?=
U2OS NUfRdlZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzxVGI4OiCq Mnm2SG1UVw>? MmH0TWM2OD1yLkG5POKyOC5yMEig{txO MmLONlU6PDR3Nk[=
SJSA-1 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXNS5FPPzJiaB?= M3f6emROW09? NVnZS2ZCUUN3ME2wMlExOMLzMD6wNVAh|ryP NWHNOGU5OjV7NES1OlY>
494H Ml3nRZBweHSxc3nzJGF{e2G7 MnLmNE4zPS9yLkWvNU4xKM7:TR?= M3:y[lI1KGh? NF3UPXlFVVOR NGO4U5VqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MmLZNlU6PDR3Nk[=
148I NU[wb3BWSXCxcITvd4l{KEG|c3H5 NWe0WXpUOC5{NT:wMlUwOS5yIN88US=> MonMNlQhcA>? M4HZR2ROW09? M4D5R4lv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? M3X0ZlI2QTR2NU[2
OS17 NF;PSY9CeG:ydH;zbZMhSXO|YYm= MXmwMlI2NzBwNT:xMlAh|ryP MW[yOEBp NEXvdFBFVVOR M3H4ZYlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NYPXelM2OjV7NES1OlY>
494H NUPT[IZrSXCxcITvd4l{KEG|c3H5 NFXkc4My6oDLzszN NIG2[pU1QCCq MlHsSG1UVw>? NYTHVGcycW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 Ml62NlU6PDR3Nk[=
148I NIDOfoJCeG:ydH;zbZMhSXO|YYm= M1PvVlHjiIoQvF2= NUfMSVZVPDhiaB?= M2\u[GROW09? MofqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M3zrXlI2QTR2NU[2
OS17 M4jnNGFxd3C2b4Ppd{BCe3OjeR?= M1LKUVHjiIoQvF2= NWjyZXRrPDhiaB?= MofTSG1UVw>? Moe4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MWiyOVk1PDV4Nh?=
MOLM13 MnywRZBweHSxc3nzJGF{e2G7 NIjtSm0zPTBibl2= MlTqOFghcA>? Ml;SSG1UVw>? M2XLZYlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= MkK0NlUxPTN6MkW=
MV4-11  Mo\IRZBweHSxc3nzJGF{e2G7 Mne3NlUxKG6P NUjEOJZHPDhiaB?= M2D6b2ROW09? Ml6zbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk M2PuRVI2ODV|OEK1
MOLM13 NGfTSIFHfW6ldHnvckBCe3OjeR?= MknhNlUxKG6P Mn;FNlQhcA>? MUTEUXNQ MUHlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MUGyOVA2Ozh{NR?=
MV4-11  Mni0SpVv[3Srb36gRZN{[Xl? NUT0RmJwOjVyIH7N MXWyOEBp M2\LeGROW09? M4ize4VvcGGwY3XzJJF2cXqjcoTpcoljNWmwZIXj[YQhdW:{ZTDwNlEtKEKLTTygZY5lKGOuZXH2[YQhWEGUUB?= M37JRlI2ODV|OEK1
MOLM13 MYDBdI9xfG:|aYOgRZN{[Xl? MUmyOVAhdk1? NXzYb5dlPDhiaB?= M{XxNWROW09? MkHPbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NVi3flFROjVyNUO4NlU>
MV4-11  NH\OcZpCeG:ydH;zbZMhSXO|YYm= MXeyOVAhdk1? NH\POXM1QCCq M4HFZmROW09? Mny4bY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? MmXwNlUxPTN6MkW=
Hela Ml36R4VtdCCYaXHibYxqfHliQYPzZZk> M1Px[VAuPTByIH7N MWm3NkBp M2i4U2ROW09? M4nw[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mn;4NlUxODl{OUW=
HBL-1 NFPpOWNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnXlNE02ODBibl2= NIHR[5I4OiCq MV7EUXNQ M{fk[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NV7Q[VdTOjVyMEmyPVU>
HLY-1 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmfsNE02ODBibl2= NUjYfo5rPzJiaB?= MYnEUXNQ MWrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2njflI2ODB7Mkm1
OCI-Ly3 MnHqR4VtdCCYaXHibYxqfHliQYPzZZk> NGHQ[YkxNTVyMDDuUS=> M3qxWVczKGh? M{T0OWROW09? NHvqPZBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYeyOVAxQTJ7NR?=
OCI-Ly10 MlqyR4VtdCCYaXHibYxqfHliQYPzZZk> M4q0cFAuPTByIH7N Mle4O|IhcA>? NFzrXmRFVVOR M1fFUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYCyOVAxQTJ7NR?=
SU-DHL-4 Mm\hR4VtdCCYaXHibYxqfHliQYPzZZk> MlTNNE02ODBibl2= M3jwTlczKGh? NU\hdll[TE2VTx?= MUfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV2yOVAxQTJ7NR?=
SU-DHL-5 M170OWNmdGxiVnnhZoltcXS7IFHzd4F6 NXvVcHU6OC13MECgcm0> M17DXlczKGh? NIrhOW9FVVOR NWrWTXRX\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIHMT|kzPTByOUK5OS=>
SU-DHL-6 NGnobXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXnDeoFWOC13MECgcm0> NF;HUGI4OiCq NULiZYVVTE2VTx?= NHe2T5hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWf1Voc5OjVyMEmyPVU>
SU-DHL-10 NVHWTWQ5S2WubDDWbYFjcWyrdImgRZN{[Xl? NED4V4wxNTVyMDDuUS=> NFfoZmU4OiCq M2nxPGROW09? MXXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXOyOVAxQTJ7NR?=
RC-K8 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4ThWVAuPTByIH7N MnW2O|IhcA>? M375TmROW09? Mn7T[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWmyOVAxQTJ7NR?=
OCI-Ly8 M1T2N2NmdGxiVnnhZoltcXS7IFHzd4F6 NFv0UZUxNTVyMDDuUS=> NH;uT|M4OiCq M3rjRmROW09? NYDLPWlS\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MorPNlUxODl{OUW=
OCL-Ly18 NVvkcphJS2WubDDWbYFjcWyrdImgRZN{[Xl? M136cFAuPTByIH7N Mo\oO|IhcA>? MVnEUXNQ NITqSpBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUTjPVdMOjVyMEmyPVU>
OCI-Ly3 M1i5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSxO|IwOjVyL{WwNEBvVQ>? MmLTNk84KGR? MoT1SG1UVw>? NU\hUFNxcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MXmyOVAxQTJ7NR?=
OCI-Ly8 NFO0eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexO|IwOjVyL{WwNEBvVQ>? NEDldWszNzdiZB?= NY[0S2hrTE2VTx?= NELhbG9qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg Mo\ZNlUxODl{OUW=
SU-DHL-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvw[5AyPzJxMkWwM|UxOCCwTR?= NW\lUY1NOi95IHS= NUm4SYxWTE2VTx?= NELoSHVqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M124SFI2ODB7Mkm1
SU-DHL-10 NV\Nd|RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXoboIyPzJxMkWwM|UxOCCwTR?= MVuyM|ch\A>? NXroW3F{TE2VTx?= NIDPcVRqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NHfE[3gzPTByOUK5OS=>
OCI-Ly3 M3u4RmFxd3C2b4Ppd{BCe3OjeR?= NGXMd|UyPzJxMkWwJI5O MXy3[C=> MYXEUXNQ MX;pcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= M1TtclI2ODB7Mkm1
OCI-Ly8 NXXuO5djSXCxcITvd4l{KEG|c3H5 M{e4N|E4Oi9{NUCgcm0> Ml7RO4Q> M33XOWROW09? NIH1PXRqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NVHKRnlkOjVyMEmyPVU>
SU-DHL-4 MYLBdI9xfG:|aYOgRZN{[Xl? M37mblE4Oi9{NUCgcm0> NYrmVnM3P2R? MXfEUXNQ MXzpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NUS3enlYOjVyMEmyPVU>
SU-DHL-10 MkLGRZBweHSxc3nzJGF{e2G7 M1;mTFE4Oi9{NUCgcm0> MoTpO4Q> NGOxc29FVVOR MlHtbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 M13VcFI2ODB7Mkm1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
体内研究 (+)-JQ1(50 mg/kg)处理携带NMC 797移植瘤的小鼠,抑制肿瘤生长。(+)-JQ1(50 mg/kg) 抹消掉携带NMC 797移植瘤的小鼠的NUT核斑点, 与竞争性结合到核染色质相一致。(+)-JQ1(50 mg/kg)处理NMC 797移植瘤, 显著诱导(31级)角蛋白表达。(+)-JQ1(50 mg/kg)处理携带NMC移植瘤的小鼠模型,促进分化,肿瘤衰退,延长寿命。[1](+)-JQ1(50 mg/kg)处理静脉注射MM.1S-luc+细胞,携带原位移植瘤的SCID米色小鼠,与对照组动物相比,显著延长小鼠的总生存期。[2](+)-JQ1(50 mg/kg,腹腔注射)处理携带Raji移植瘤的小鼠,显著提高小鼠寿命。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: MC 11060细胞
  • Concentrations: ~500 nM
  • Incubation Time: 48小时
  • Method:

    细胞按每孔500个接种在白色, 384孔微孔板,孔中含总体为50 μL的培养基。797, TT和TE10细胞生长在含1% Penicillin/Streptomycin 和 10% FBS的DMEM培养基上。Per403细胞生长在含1 % Penicillin/Streptomycin和20% FBS的DMEM 培养基上。病患衍生的NMC 11060细胞生长在含10% FBS 和1% Penicillin/Streptomycin的RPMI培养基上。通过自动化针转移机将(+)-JQ1置于微量检测板上。使细胞裂解,通过增殖试验测评孔中的总ATP含量。根据剂量,重复测量分析,通过逻辑回归(GraphPad Prism)计算IC50。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带NMC 797移植瘤的小鼠
  • Dosages: 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 456.99
化学式

C23H25ClN4O2S

CAS号 1268524-70-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How can I reconstitute the compound for in vivo injection?

  • 回答:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Target Protein Ligand Inhibitors with Unique Features

Tags: 购买(+)-JQ1 | (+)-JQ1供应商 | 采购(+)-JQ1 | (+)-JQ1价格 | (+)-JQ1生产 | 订购(+)-JQ1 | (+)-JQ1代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID